Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03472040 · ClinicalTrials.gov registry record · Phase 2
A Long Term Safety Study of BCX7353 in Hereditary Angioedema
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 387
- Enrollment target
NCT03472040 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 387 participants.
The verdict
NCT03472040, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 387 participants
- Enrollment target
Study Summary
This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II Hereditary Angioedema (HAE).
Interventions
- DRUG BCX7353
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2018-02-16 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03472040
The ClinicalTrials.gov registry entry for NCT03472040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BCX7353 is the first listed.
NCT03472040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03472040 about?
NCT03472040 is a clinical study titled "A Long Term Safety Study of BCX7353 in Hereditary Angioedema". This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II Hereditary Angioedema (HAE).
What is the current status of trial NCT03472040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 387 participants. The study started on 2018-02-16. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT03472040?
The interventions under investigation include: BCX7353 (DRUG).
Who is sponsoring clinical trial NCT03472040?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.